Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.